Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia

Viruses. 2024 Apr 18;16(4):628. doi: 10.3390/v16040628.

Abstract

The prevalence of hepatitis B and delta viruses (HBV/HDV) among people who use drugs (PWUD) remains largely unknown. In the context of one Philadelphia-based harm reduction organization (HRO), this study aimed to assess HBV/HDV prevalence and facilitate linkage to care. Participants completed a demographic HBV/HDV risk factor survey and were screened for HBV and reflexively for HDV if positive for HBV surface antigen or isolated core antibody. Fisher's exact tests and regression were used to understand relationships between risks and HBV blood markers. Of the 498 participants, 126 (25.3%) did not have hepatitis B immunity, 52.6% had been vaccinated against HBV, and 17.9% had recovered from a past infection. Eleven (2.2%) participants tested positive for isolated HBV core antibody, 10 (2.0%) for HBV surface antigen, and one (0.2%) for HDV antibody. History of incarceration was associated with current HBV infection, while transactional sex and experience of homelessness were predictive of previous exposure. This study found high rates of current and past HBV infection, and a 10% HBV/HDV co-infection rate. Despite availability of vaccine, one quarter of participants remained vulnerable to infection. Findings demonstrate the need to improve low-threshold HBV/HDV screening, vaccination, and linkage to care among PWUD. The study also identified gaps in the HBV/HDV care cascade, including lack of point-of-care diagnostics and lack of support for HROs to provide HBV services.

Keywords: harm reduction; hepatitis B; hepatitis delta; liver cancer; people who inject drugs; people who use drugs; population health; viral hepatitis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Drug Users / statistics & numerical data
  • Female
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B* / epidemiology
  • Hepatitis B* / immunology
  • Hepatitis B* / prevention & control
  • Hepatitis D* / diagnosis
  • Hepatitis D* / epidemiology
  • Hepatitis D* / immunology
  • Hepatitis Delta Virus / genetics
  • Hepatitis Delta Virus / immunology
  • Humans
  • Male
  • Mass Screening*
  • Middle Aged
  • Philadelphia / epidemiology
  • Prevalence
  • Risk Factors
  • Young Adult

Substances

  • Hepatitis B Surface Antigens